Claims for Patent: 10,851,174

✉ Email this page to a colleague

Summary for Patent: 10,851,174

Title:	Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof
Abstract:	A chemoenzymatic method for the preparation of a core-fucoslyated glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of a fucosylated GlcNAc-protein and fucosylated GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of an endoglycosidase (ENGase) selected from Endo;F1, Endo-F2, Endo-F3, Endo-D and related glycosynthase mutants to transfer the oligosaccharide moiety to the acceptor and yield the structure defined core-fucosylated glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of fucosylated glycoprotein or fucosylated glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody to include a predetermined sugar chain to replace a heterogeneous sugar chain, are also described.
Inventor(s):	Wang Lai-Xi, Huang Wei, Giddens John
Assignee:	UNIVERSITY OF MARYLAND, BALTIMORE
Application Number:	US13411733
Patent Claims:

Details for Patent 10,851,174

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	December 22, 1994	10,851,174	2032-03-05
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	December 10, 1997	10,851,174	2032-03-05
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	May 12, 1998	10,851,174	2032-03-05
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	January 02, 2003	10,851,174	2032-03-05
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	June 19, 1998	10,851,174	2032-03-05
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	July 23, 2004	10,851,174	2032-03-05
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,851,174

Subscribe to access the full database, or Get Started Free
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2013120066	⤷ Get Started Free
United States of America	9850473	⤷ Get Started Free
United States of America	9845360	⤷ Get Started Free
United States of America	9434786	⤷ Get Started Free
United States of America	9175326	⤷ Get Started Free
United States of America	2021061868	⤷ Get Started Free
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.